Oura Buys AI Primary Care Startup Counsel Health for $625 Million
The Finnish smart ring maker pivots from tracking health metrics to delivering active medical care with its biggest acquisition to date.
Finnish smart ring maker Oura has entered into a definitive agreement to acquire Counsel Health, an artificial intelligence-native primary care startup, for $625 million in cash. The blockbuster deal, expected to close by the end of 2026, marks a watershed moment for the digital health sector as wearables attempt to bridge the gap between tracking physiological data and providing direct clinical care.
Oura, widely known for its health-tracking hardware and substantial consumer subscription base, has been signaling a pivot toward active medical integration. Counsel Health, based in Boston and led by Dr. Muthu Alagappan, provides a text-based medical triage system powered by AI, backed by a proprietary "Clinician Cockpit" and real licensed physicians. Together, they aim to create a "24-7 doctor in your pocket," allowing users to instantly act on concerning health metrics flagged by their ring.
From Biometrics to Direct Care
Since June 2026, Counsel Health's platform has already been integrated directly into the Oura ecosystem. Users who notice an anomaly in their sleep, readiness, or stress metrics have been able to chat with Counsel’s medical AI, which draws upon the user’s continuous biometric data. If the AI determines a need for further intervention, the system connects the user with a board-certified doctor who can offer diagnoses, issue prescriptions, order lab tests, or make specialist referrals.
Historically, consumer wearables have faced a major limitation: they excel at telling users something is wrong, but stumble at telling them what to do next. By bringing Counsel Health’s physician network and automated triage capabilities in-house, Oura aims to overcome this friction. The acquisition effectively closes the loop, seamlessly transitioning consumers from automated physiological alerts to billable clinical encounters.
Financials and Market Context
The all-cash transaction underscores Oura's substantial financial war chest, despite recent market turbulence. In September 2026, the company indefinitely delayed a highly anticipated $2.2 billion initial public offering (IPO), citing widespread market uncertainty. However, Oura remains highly profitable, reporting a 153% revenue surge to $533 million for the quarter ending September 30, and nearly $1.8 billion in revenue for the fiscal year. Counsel Health, which previously raised a $25 million Series A round in 2025 led by Andreessen Horowitz and GV, represents Oura's most aggressive bet on vertical integration to date.
Upon the deal's closing, Counsel Health's 70 employees will officially join Oura. Dr. Alagappan will assume the newly created role of Chief Clinical AI Officer, ensuring that the company's continuous care expansion remains anchored by rigorous clinical safety protocols and physician oversight. Furthermore, Oura plans to maintain and grow Counsel Health’s enterprise partnerships, extending the AI-native care model to employers, health plans, and a recently announced collaboration with the Centers for Medicare & Medicaid Services (CMS).
The Regulatory Horizon
While the market logic is sound, integrating an AI primary care provider into a consumer tech platform is not without substantial regulatory and ethical hurdles. Critics argue that allowing a consumer gadget company to manage licensed physicians could invite heightened scrutiny from the FDA regarding clinical decision-support software. Furthermore, strict state-by-state telemedicine licensing and HIPAA privacy rules mean that the line between actionable health alerts and diagnostic medical advice must be navigated with extreme care.
Ultimately, Oura’s $625 million bet signals a structural shift in the wearable market from passive surveillance to active medical intervention. If Oura successfully integrates Counsel Health’s AI-powered triage and physician network, it could establish a formidable moat that rivals like Apple, Google, and Whoop will struggle to cross. However, the true test will not be won with hardware or software, but in proving to patients and regulators that a smart ring can safely function as a trusted front door to the healthcare system.